Search

Your search keyword '"Latif, Farhana"' showing total 316 results
Start Over Author "Latif, Farhana"
316 results on '"Latif, Farhana"'

2. Added prognostic value of visually estimated coronary artery calcium among heart transplant recipients

Author

Clerkin, Kevin J., Sewanan, Lorenzo, Griffin, Jan M., DeFilippis, Ersilia M., Peng, Boyu, Chernovolenko, Margarita, Harris, Erin, Prasad, Nikil, Colombo, Paolo C., Yuzefpolskaya, Melana, Fried, Justin, Raikhelkar, Jayant, Topkara, Veli K., Castillo, Michelle, Lam, Elaine Y., Latif, Farhana, Takeda, Koji, Uriel, Nir, Sayer, Gabriel, and Einstein, Andrew J.

Published
2024
Full Text
View/download PDF

3. Alterations in the sarcopenia index are associated with inflammation, gut, and oral microbiota among heart failure, left ventricular assist device, and heart transplant patients

Author

Yuzefpolskaya, Melana, Bohn, Bruno, Ladanyi, Annamaria, Pinsino, Alberto, Braghieri, Lorenzo, Carey, Matthew R., Clerkin, Kevin, Sayer, Gabriel T., Latif, Farhana, Koji, Takeda, Uriel, Nir, Nandakumar, Renu, Uhlemann, Anne-Catrin, Colombo, Paolo C., and Demmer, Ryan T.

Published
2024
Full Text
View/download PDF

13. CAV Trajectories Among Patients With No or Mild CAV at 10 Years Posttransplant.

Author

Harris, Erin, Prasad, Nikil, Skoll, Devin, Kumar, Sambhavi Sneha, Fried, Justin, Topkara, Veli, Raikhelkar, Jayant K., DeFilippis, Ersilia M., Latif, Farhana, Yuzefpolskaya, Melana, Colombo, Paolo C., Uriel, Nir, Takeda, Koji, Sayer, Gabriel T., and Clerkin, Kevin J.

Subjects
HEART transplantation, CORONARY artery disease, CARDIOVASCULAR diseases, VASCULAR diseases, ANGIOGRAPHY
Abstract

Cardiac allograft vasculopathy (CAV) is a major cause of morbidity and mortality following heart transplantation (HT). Prior studies identified distinct CAV trajectories in the early post‐HT period with unique predictors, but the evolution of CAV in later periods is not well‐described. This study assessed the prevalence of late CAV progression and associated risk factors in HT recipients with ISHLT CAV 0/1 at 10 years post‐HT. Consecutive adult patients who underwent HT from January 2000 to December 2008 were evaluated and grouped by CAV trajectories into progressors (developed ISHLT CAV 2/3) or nonprogressors (remained ISHLT CAV 0/1). A total of 130 patients were included with a median age at angiography of 61.7 years and a median follow‐up time of 4.8 years. 8.5% progressed to CAV 2/3, while the remaining 91.5% were nonprogressors. Progression was not associated with death or retransplantation (27.3% [progressor] vs. 21.0% [nonprogressor], p = 0.70). These data may inform shared decision‐making about late CAV screening. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Alterations in Sarcopenia Index are Associated with Inflammation, Gut and Oral Microbiota among Heart Failure, Left Ventricular Assist Device and Heart Transplant Patients.

Author

Yuzefpolskaya, Melana, primary, Bohn, Bruno, additional, Ladanyi, Annamaria, additional, Pinsino, Alberto, additional, Braghieri, Lorenzo, additional, Carey, Matthew R., additional, Clerkin, Kevin, additional, Sayer, Gabriel T., additional, Latif, Farhana, additional, Koji, Takeda, additional, Uriel, Nir, additional, Nandakumar, Renu, additional, Uhlemann, Anne-Catrin, additional, Colombo, Paolo C., additional, and Demmer, Ryan T., additional

Published
2024
Full Text
View/download PDF

16. Long‐term outcomes for pediatric heart transplant recipients transitioning to adult care teams

Author

Donald, Elena M., primary, Oren, Daniel, additional, DeFilippis, Ersilia M., additional, Rubinstein, Gal, additional, Moeller, Catherine M., additional, Lee, Hannah Y., additional, Maldonado, Alejandro, additional, Portera, Mary Virginia, additional, Fuselier, Byron, additional, Jackson, Ruslana, additional, Clerkin, Kevin. J., additional, Fried, Justin. A., additional, Raikhelkar, Jayant, additional, Lee, Sun Hi, additional, Latif, Farhana, additional, Lytrivi, Irene D., additional, Zuckerman, Warren A., additional, Richmond, Marc E., additional, Sayer, Gabriel, additional, and Uriel, Nir, additional

Published
2024
Full Text
View/download PDF

17. Utility of a fusion protein T‐cell co‐stimulation blocker Belatacept in heart transplant recipients: Real world experience from a high volume center

Author

Oren, Daniel, primary, Uriel, Matan, additional, Moeller, Cathrine M., additional, Valledor, Andrea Fernandez, additional, DeFilippis, Ersilia M., additional, Lotan, Dor, additional, Colombo, Paolo C., additional, Yuzefpolskaya, Melana, additional, Topkara, Veli K., additional, Clerkin, Kevin J., additional, Raikhelkar, Jayant K., additional, Fried, Justin A., additional, Oh, David (Kyung Taek), additional, Bae, David, additional, Lin, Eddie, additional, Theodoropoulos, Kleanthis, additional, Naka, Yoshifumi, additional, Takeda, Koji, additional, Choe, Jason, additional, Jennings, Douglas L., additional, Majure, David, additional, Latif, Farhana, additional, Sayer, Gabriel, additional, and Uriel, Nir, additional

Published
2024
Full Text
View/download PDF

19. Pre‐operative pectoralis muscle area index is associated with biomarkers of inflammation and endotoxemia and predicts clinical outcomes after left ventricular assist device implantation: A cohort study.

Author

Carey, Matthew R., Ladanyi, Annamaria, Nishikawa, Mia, Bordon, Abraham, Leb, Jay S., Pinsino, Alberto, Driggin, Elissa, Latif, Farhana, Sayer, Gabriel T., Clerkin, Kevin J., Takeda, Koji, Uriel, Nir, Colombo, Paolo C., and Yuzefpolskaya, Melana

Subjects
PECTORALIS muscle, HEART assist devices, COMPUTED tomography, ENDOTOXEMIA, GASTROINTESTINAL hemorrhage, SARCOPENIA
Abstract

Background: Pre‐left ventricular assist device (LVAD) pectoralis muscle assessment, an estimate of sarcopenia, has been associated with postoperative mortality and gastrointestinal bleeding, though its association with inflammation, endotoxemia, length‐of‐stay (LOS), and readmissions remains underexplored. Methods: This was a single‐center cohort study of LVAD patients implanted 1/2015–10/2018. Preoperative pectoralis muscle area was measured on chest computed tomography (CT), adjusted for height squared to derive pectoralis muscle area index (PMI). Those with PMI in the lowest quintile were defined as low‐PMI cohort; all others constituted the reference cohort. Biomarkers of inflammation (interleukin‐6, adiponectin, tumor necrosis factor‐α [TNFα]) and endotoxemia (soluble (s)CD14) were measured in a subset of patients. Results: Of the 254 LVAD patients, 95 had a preoperative chest CT (median days pre‐LVAD: 7 [IQR 3–13]), of whom 19 (20.0%) were in the low‐PMI cohort and the remainder were in the reference cohort. Compared with the reference cohort, the low‐PMI cohort had higher levels of sCD14 (2594 vs. 1850 ng/mL; p = 0.04) and TNFα (2.9 vs. 1.9 pg/mL; p = 0.03). In adjusted analyses, the low‐PMI cohort had longer LOS (incidence rate ratio 1.56 [95% confidence interval 1.16–2.10], p = 0.004) and higher risk of 90‐day and 1‐year readmissions (subhazard ratio 5.48 [1.88–16.0], p = 0.002; hazard ratio 1.73 [1.02–2.94]; p = 0.04, respectively). Conclusions: Pre‐LVAD PMI is associated with inflammation, endotoxemia, and increased LOS and readmissions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Hemodynamic Optimization by Invasive Ramp Test in Patients Supported With HeartMate 3 Left Ventricular Assist Device.

Author

RUBINSTEIN, GAL, MOELLER, CATHRINE M., LOTAN, DOR, SLOMOVICH, SHARON, FERNANDEZ-VALLEDOR, ANDREA, OREN, DANIEL, OH, KYUNG T., FRIED, JUSTIN A., CLERKIN, KEVIN J., RAIKHELKAR, JAYANT K., TOPKARA, VELI K., YUJI KAKU, KOJI TAKEDA, YOSHIFUMI NAKA, BURKHOFF, DANIEL, LATIF, FARHANA, MAJURE, DAVID, COLOMBO, PAOLO C., YUZEFPOLSKAYA, MELANA, and SAYER, GABRIEL T.

Published
2024
Full Text
View/download PDF

21. Cardio‐Renal‐Metabolic Outcomes Associated With the Use of GLP‐1 Receptor Agonists After Heart Transplantation.

Author

Donald, Elena M., Driggin, Elissa, Choe, Jason, Batra, Jaya, Vargas, Fabian, Lindekens, Jordan, Fried, Justin A., Raikhelkar, Jayant K., Bae, David J., Oh, Kyung T., Yuzefpolskaya, Melana, Colombo, Paolo C., Latif, Farhana, Sayer, Gabriel, Uriel, Nir, Clerkin, Kevin J., and DeFilippis, Ersilia M.

Subjects
HEART transplantation, TYPE 2 diabetes, GLUCAGON-like peptide-1 agonists, WEIGHT loss, GLYCEMIC control
Abstract

Background: The use of glucagon‐like‐peptide 1 receptor agonists (GLP1‐RA) has dramatically increased over the past 5 years for diabetes mellitus type 2 (T2DM) and obesity. These comorbidities are prevalent in adult heart transplant (HT) recipients. However, there are limited data evaluating the efficacy of this drug class in this population. The aim of the current study was to describe cardiometabolic changes in HT recipients prescribed GLP1‐RA at a large‐volume transplant center. Methods: We retrospectively reviewed all adult HT recipients who received GLP1‐RA after HT for a minimum of 1‐month. Cardiometabolic parameters including body mass index (BMI), lipid panel, hemoglobin A1C, estimated glomerular filtration rate (eGFR), and NT‐proBNP were compared prior to initiation of the drug and at most recent follow‐up. We also evaluated for significant dose adjustments to immunosuppression after drug initiation and adverse effects leading to drug discontinuation. Results: Seventy‐four patients were included (28% female, 53% White, 20% Hispanic) and followed for a median of 383 days [IQR 209, 613] on a GLP1‐RA. The majority of patients (n = 56, 76%) were prescribed semaglutide. The most common indication for prescription was T2DM alone (n = 33, 45%), followed by combined T2DM and obesity (n = 26, 35%). At most recent follow‐up, mean BMI decreased from 33.3 to 31.5 kg/m2 (p < 0.0001), HbA1C from 7.3% to 6.7% (p = 0.005), LDL from 78.6 to 70.3 mg/dL (p = 0.018) and basal insulin daily dose from 32.6 to 24.8 units (p = 0.0002). Conclusion: HT recipients prescribed GLP1‐RA therapy showed improved glycemic control, weight loss, and cholesterol levels during the study follow‐up period. GLP1‐RA were well tolerated and were rarely associated with changes in immunosuppression dosing. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Comparative Analysis of Ischemia‐Reperfusion Injury in Heart Transplantation: A Single‐Center Study Evaluating Conventional Ice‐Cold Storage versus the Paragonix SherpaPak Cardiac Transport System.

Author

Lotan, Dor, Moeller, Cathrine M., Rahman, Afsana, Rubinstein, Gal, Oren, Daniel, Mehlman, Yonatan, Valledor, Andrea Fernandez, DeFilippis, Ersilia M., Raikhelkar, Jayant, Clerkin, Kevin, Fried, Justin, Majure, David, Naka, Yoshifumi, Kaku, Yuji, Takeda, Koji, Oh, Kyung Taek, Yunis, Adil, Colombo, Paolo C, Yuzefpolskaya, Melana, and Latif, Farhana

Subjects
HEART transplantation, REPERFUSION injury, HEART injuries, SURGICAL complications, GRAFT rejection, CARPAL tunnel syndrome, CARDIAC amyloidosis
Abstract

Background: Since the 2018 allocation system change in heart transplantation (HT), ischemic times have increased, which may be associated with peri‐operative and post‐operative complications. This study aimed to compare ischemia reperfusion injury (IRI) in hearts preserved using ice‐cold storage (ICS) and the Paragonix SherpaPak TM Cardiac Transport System (CTS). Methods: From January 2021 to June 2022, consecutive endomyocardial biopsies from 90 HT recipients were analyzed by a cardiac pathologist in a single‐blinded manner: 33 ICS and 57 CTS. Endomyocardial biopsies were performed at three‐time intervals post‐HT, and the severity of IRI manifesting histologically as coagulative myocyte necrosis (CMN) was evaluated, along with graft rejection and graft function. Results: The incidence of IRI at weeks 1, 4, and 8 post‐HT were similar between the ICS and CTS groups. There was a 59.3% statistically significant reduction in CMN from week 1 to 4 with CTS, but not with ICS. By week 8, there were significant reductions in CMN in both groups. Only 1 out of 33 (3%) patients in the ICS group had an ischemic time >240 mins, compared to 10 out of 52 (19%) patients in the CTS group. During the follow‐up period of 8 weeks to 12 months, there were no significant differences in rejection rates, formation of de novo donor‐specific antibodies and overall survival between the groups. Conclusion: The CTS preservation system had similar rates of IRI and clinical outcomes compared to ICS despite longer overall ischemic times. There is significantly more recovery of IRI in the early post operative period with CTS. This study supports CTS as a viable option for preservation from remote locations, expanding the donor pool. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. A change of heart: Characteristics and outcomes of multiple cardiac retransplant recipients

Author

Batra, Jaya, primary, DeFilippis, Ersilia M., additional, Clerkin, Kevin, additional, Bae, David, additional, Oh, Kyung Taek, additional, Lotan, Dor, additional, Topkara, Veli K., additional, Lee, Sun Hi, additional, Latif, Farhana, additional, Colombo, Paolo, additional, Yuzefpolskaya, Melana, additional, Raikhelkar, Jayant, additional, Majure, David T., additional, Sayer, Gabriel, additional, and Uriel, Nir, additional

Published
2023
Full Text
View/download PDF

26. Pediatric Heart Transplantation: Transitioning to Adult Care (TRANSIT): Feasibility of a Pilot Randomized Controlled Trial

Author

Grady, Kathleen L., Andrei, Adin-Cristian, Shankel, Tamara, Chinnock, Richard, Miyamoto, Shelley D., Ambardekar, Amrut V., Anderson, Allen, Addonizio, Linda, Latif, Farhana, Lefkowitz, Debra, Goldberg, Lee R., Hollander, Seth A., Pham, Michael, Van't Hof, Kathleen, Weissberg-Benchell, Jill, Yancy, Clyde, Liu, Menghan, Melody, Nichole, and Pahl, Elfriede

Published
2019
Full Text
View/download PDF

29. Pumping for Two: Pregnancy in Patients Supported With a Left Ventricular Assist Device

Author

Oren, Daniel, primary, Moeller, Cathrine M., additional, Haythe, Jennifer H., additional, Rubinstein, Gal, additional, Fernandez Valledor, Andrea, additional, Lotan, Dor, additional, Rosenblum, Hannah, additional, Colombo, Paolo C., additional, Yuzefpolskaya, Melana, additional, Topkara, Veli K., additional, Clerkin, Kevin J., additional, Raikhelkar, Jayant K., additional, Fried, Justin A., additional, Naka, Yoshifumi, additional, Takeda, Koji, additional, Latif, Farhana, additional, Sayer, Gabriel, additional, and Uriel, Nir, additional

Published
2023
Full Text
View/download PDF

30. The utilization of molecular microscope in management of heart transplant recipients in the era of noninvasive monitoring

Author

Mehlman, Yonatan, primary, Fernendez, Andrea, additional, Moeller, Cathrine, additional, Rubinstein, Gal, additional, Lotan, Dor, additional, Rahman, Salwa, additional, Oh, Kyung T., additional, Bae, David, additional, DeFilippis, Ersilia M., additional, Lin, Edward F., additional, Lee, Sun Hi, additional, Raikhelkar, Jayant K., additional, Fried, Justin, additional, Theodoropoulos, Kleanthis, additional, Colombo, Paolo C., additional, Yuzefpolskaya, Melana, additional, Latif, Farhana, additional, Clerkin, Kevin J., additional, Sayer, Gabriel T., additional, and Uriel, Nir, additional

Published
2023
Full Text
View/download PDF

32. Alterations in Sarcopenia Index are Associated with Inflammation, Gut and Oral Microbiota among Heart Failure, Left Ventricular Assist Device and Heart Transplant Patients.

Author

Yuzefpolskaya, Melana, primary, Bohn, Bruno, additional, Ladanyi, Annamaria, additional, Pinsino, Alberto, additional, Braghieri, Lorenzo, additional, Carey, Matthew, additional, Clerkin, Kevin J, additional, Sayer, Gabriel T, additional, Latif, Farhana, additional, Takeda, Koji, additional, Uriel, Nir, additional, Nandakumar, Renu, additional, Uhlemann, Anne-Catrin, additional, Colombo, Paolo C., additional, and Demmer, Ryan T, additional

Published
2023
Full Text
View/download PDF

33. A change of heart: Characteristics and outcomes of multiple cardiac retransplant recipients.

Author

Batra, Jaya, DeFilippis, Ersilia M., Clerkin, Kevin, Bae, David, Oh, Kyung Taek, Lotan, Dor, Topkara, Veli K., Lee, Sun Hi, Latif, Farhana, Colombo, Paolo, Yuzefpolskaya, Melana, Raikhelkar, Jayant, Majure, David T., Sayer, Gabriel, and Uriel, Nir

Subjects
PATIENT experience, HEART transplantation, CHILD patients, PATIENTS' attitudes, DEATH rate
Abstract

Background: Among heart transplant (HT) recipients who develop advanced graft dysfunction, cardiac re‐transplantation may be considered. A smaller subset of patients will experience failure of their second allograft and undergo repeat re‐transplantation. Outcomes among these individuals are not well‐described. Methods: Adult and pediatric patients in the United Network for Organ Sharing (UNOS) registry who received HT between January 1, 1990 and December 31, 2020 were included. Results: Between 1990 and 2020, 90 individuals received a third HT and three underwent a fourth HT. Recipients were younger than those undergoing primary HT (mean age 32 years). Third HT was associated with significantly higher unadjusted rates of 1‐year mortality (18% for third HT vs. 13% for second HT vs. 9% for primary HT, p <.001) and 10‐year mortality (59% for third HT vs. 42% for second HT vs. 37% for primary HT, p <.001). Mortality was highest amongst recipients aged >60 years and those re‐transplanted for acute graft failure. Long‐term rates of CAV, rejection, chronic dialysis, and hospitalization for infection were also higher. Conclusions: Third HT is associated with higher morbidity and mortality than primary HT. Further consensus is needed regarding appropriate organ stewardship for this unique subgroup. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. The Impact Of Preexisting Hematologic Disorders On Morbidity And Mortality Following Heart Transplantation

Author

Carey, Matthew R, primary, Ladanyi, Annamaria, additional, Mehlman, Yonatan, additional, Eisenbeger, Andrew, additional, Molinsky, Rebecca L., additional, Demmer, Ryan T., additional, Aaron, Justin G, additional, Latif, Farhana, additional, Takeda, Koji, additional, Sayer, Gabriel T., additional, Uriel, Nir, additional, Colombo, Paolo C, additional, and Yuzefpolskaya, Melana, additional

Published
2023
Full Text
View/download PDF

37. Utility Of First Biopsy Performed Under 10 Days Following Orthotopic Heart Transplantation

Author

Lotan, Dor, primary, Oren, Daniel, additional, Uriel, Matan, additional, Clerkin, Kevin, additional, Yuzefpolskaya, Melana, additional, Colombo, Paolo C., additional, Restaino, Susan, additional, Raikhelkar, Jayant, additional, Latif, Farhana, additional, Kleet, Audrey, additional, Gaine, Maureen, additional, Mabasa, Angelo, additional, Sayer, Gabriel, additional, and Uriel, Nir, additional

Published
2023
Full Text
View/download PDF

38. Combined heart and liver transplantation in a patient supported by left ventricular assist device (LVAD) with propionic acidemia

Author

Lotan, Dor, primary, DeFilippis, Ersilia M., additional, Oren, Daniel, additional, Vinogradsky, Alice, additional, Rubinstein, Gal, additional, Mathur, Abhishek, additional, Takeda, Koji, additional, Hua, May, additional, Gaglio, Paul J., additional, Szabolcs, Matthias J., additional, Sayer, Gabriel, additional, Uriel, Nir, additional, Iglesias, Alejandro Daniel, additional, and Latif, Farhana, additional

Published
2023
Full Text
View/download PDF

40. Early post‐transplant leukopenia in heart transplant recipients and its impact on outcomes

Author

Batra, Jaya, primary, DeFilippis, Ersilia M., additional, Golob, Stephanie, additional, Lumish, Heidi, additional, Clerkin, Kevin, additional, Topkara, Veli K., additional, Restaino, Susan, additional, Lee, Sun Hi, additional, Latif, Farhana, additional, Raikhelkar, Jayant, additional, Fried, Justin, additional, Oh, Kyung Taek, additional, Lin, Edward, additional, Colombo, Paolo C., additional, Yuzefpolskaya, Melana, additional, Sayer, Gabriel, additional, and Uriel, Nir, additional

Published
2023
Full Text
View/download PDF

44. Letermovir for cytomegalovirus prophylaxis in high‐risk heart transplant recipients

Author

Golob, Stephanie, primary, Batra, Jaya, additional, DeFilippis, Ersilia M., additional, Uriel, Matan, additional, Carey, Matt, additional, Gaine, Maureen, additional, Mabasa, Angelo, additional, Fried, Justin, additional, Raikelkar, Jayant, additional, Restaino, Susan, additional, Hi Lee, Sun, additional, Latif, Farhana, additional, Yuzefpolskaya, Melana, additional, Colombo, Paolo C., additional, Choe, Jason, additional, Majure, David, additional, Jennings, Douglas, additional, Pereira, Marcus R., additional, Clerkin, Kevin, additional, Sayer, Gabriel, additional, and Uriel, Nir, additional

Published
2022
Full Text
View/download PDF

47. Temporal shifts in safety and efficacy profile of mycophenolate mofetil 2 g versus 3 g daily early after heart transplantation

Author

Braghieri, Lorenzo, primary, Jennings, Douglas L., additional, Bohn, Bruno, additional, Habal, Marlena, additional, Pinsino, Alberto, additional, Mondellini, Giulio M., additional, Ladanyi, Annamaria, additional, Latif, Farhana, additional, Clerkin, Kevin, additional, Restaino, Susan, additional, Kurlansky, Paul, additional, Takeda, Koji, additional, Naka, Yoshifumi, additional, Demmer, Ryan T., additional, Sayer, Gabriel T., additional, Uriel, Nir, additional, Colombo, Paolo C., additional, and Yuzefpolskaya, Melana, additional

Published
2022
Full Text
View/download PDF

50. PCSK9 inhibitors safely and effectively lower LDL after heart transplantation: a systematic review and meta-analysis

Author

Jennings, Douglas L., primary, Sultan, Lina, additional, Mingov, Jennifer, additional, Choe, Jason, additional, Latif, Farhana, additional, Restaino, Susan, additional, Clerkin, Kevin, additional, Habal, Marlena V., additional, Colombo, Paolo C., additional, Yuzefpulskaya, Melana, additional, Sayer, Gabriel, additional, Uriel, Nir, additional, and Baker, William L., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results